Restart

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 7, 2024
Head, Restart, Neoplasm, Food, Government, Safety, Lawrence, Massachusetts, PMDA, Patient, Carcinoma, D&O, Brain, Lung cancer, Clinical trial, Alpha, G&A, Radiation, Pancreatic cancer, Liver disease, Pharmaceutical industry

We are also exploring the addition of new clinical trials in the U.S., based upon recent positive regulatory feedback.

Key Points: 
  • We are also exploring the addition of new clinical trials in the U.S., based upon recent positive regulatory feedback.
  • The Alpha DaRT procedure was deemed technically successful in all five cases, with Alpha DaRT sources successfully inserted into the target tumors.
  • Targeting completion of patient recruitment in the ReSTART pivotal U.S. multi-center trial in recurrent cutaneous squamous cell carcinoma in H2 2024.
  • The Company expects that this cash balance will be sufficient to fund operations for at least two years.

StoneRidge Centers Transforms Mental Health with Groundbreaking Approach

Retrieved on: 
Wednesday, February 14, 2024
TMS, Anxiety, IOP, Mental health, Francisco Partners, Physician, Growth, Bed, Hospital, DSM-IV codes, Tic disorder, Transcranial magnetic stimulation, Health, Depression, Patient, Restart, Acute stress disorder, PTSD, ADHD, Trust, OCD, Spectrum, Brain, Environment

Prescott Valley, Arizona, Feb. 14, 2024 (GLOBE NEWSWIRE) -- StoneRidge Centers in Prescott Valley, Arizona, revolutionizes mental health care with its groundbreaking Transcranial Magnetic Stimulation (TMS).

Key Points: 
  • Prescott Valley, Arizona, Feb. 14, 2024 (GLOBE NEWSWIRE) -- StoneRidge Centers in Prescott Valley, Arizona, revolutionizes mental health care with its groundbreaking Transcranial Magnetic Stimulation (TMS).
  • StoneRidge was founded by Mark Collins, DO, to address the shortcomings he observed in traditional inpatient mental health and rehabilitation facilities.
  • StoneRidge offers various treatments tailored to address the unique needs of individuals struggling with mental health challenges.
  • To continue fulfilling its mission of reshaping mental health care, StoneRidge intends to expand its reach and enhance its services to meet the growing demand for comprehensive mental health care.

Brooks Running Delivers Record Revenue in 2023, Accelerates Innovation in the New Year

Retrieved on: 
Tuesday, February 13, 2024
Sports, Fashion, Retail, Footwear, Running, 1,000,000, Strava, Multimedia, GTS, Brooks Beasts Track Club, Entrepreneurship, Investment, Growth, Mentorship, Foot, Adrenaline, World Athletics Championships, Cyber Monday, Restart, Hyperion, Gold, Brooks Sports, Shoe, Athlete, DTC, Video game

Brooks Running finished 2023 with record revenue growth of $1.2 billion, up 5% year over year, and a record 20 million+ units sold.

Key Points: 
  • Brooks Running finished 2023 with record revenue growth of $1.2 billion, up 5% year over year, and a record 20 million+ units sold.
  • In North America, revenue increased 7% year over year as the brand reached $1 billion in revenue in the region for the first time.
  • In 2023, Brooks also increased investment in growing the running industry through sustainability initiatives, community activations, and collaborations with key partners.
  • Following its spring launch, Brooks’ Future Run program impacted 245,000 youth runners through support of youth running programs, high school running teams, and coaches.

Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 16, 2023
Alpha Sigma Tau, Carcinoma, Pancreatic cancer, Neck, Liver disease, Safety, Financial result, Food, Toxicity, Hadassah Medical Center, Clinical trial, Government, Radiation, Patient, FDA, PMDA, Marketing, G&A, Restart, Lung cancer, Lawrence, Massachusetts, Trial of the century, Manager, Financial toxicity, Alpha, Coronavirus Scientific Advisory Board, Itch, Brain, Pharmaceutical industry, Medical imaging

JERUSALEM, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported third quarter 2023 financial results and provided a corporate update.

Key Points: 
  • - Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside safety and feasibility trial in similar indication currently underway in Montreal, Canada -
    JERUSALEM, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported third quarter 2023 financial results and provided a corporate update.
  • Planning treatment of the first patient in the Canadian liver metastases safety and feasibility trial in Q4 2023 or Q1 2024.
  • As of September 30, 2023, the Company had cash, restricted cash, deposits and restricted deposits in the amount of $90.1 million, compared to $105.4 million on December 31, 2022.
  • The Company expects that this cash balance will be sufficient to fund operations for at least two years.

Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board

Retrieved on: 
Tuesday, October 24, 2023
Radiation, FDA, Food, Therapy, Prostate Cancer Foundation, Flagship Pioneering, Head, Monroe Dunaway Anderson, Skin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Restart, Partnership, Immunotherapy, University, Squamous-cell carcinoma, MD Anderson Cancer Center, Alpha, Cancer, Patient, Glioblastoma, Alpha Sigma Tau, Neck, Coronavirus Scientific Advisory Board, Pharmaceutical industry

JERUSALEM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Stephen M. Hahn, M.D., former commissioner of the U.S. Food and Drug Administration (“FDA”), has joined its Scientific Advisory Board.

Key Points: 
  • JERUSALEM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Stephen M. Hahn, M.D., former commissioner of the U.S. Food and Drug Administration (“FDA”), has joined its Scientific Advisory Board.
  • “I am pleased to welcome Dr. Hahn to the Alpha Tau Scientific Advisory Board at an ideal time in the Company’s growth trajectory,” said Company CEO Uzi Sofer.
  • He previously served as FDA Commissioner from 2019 to 2021, overseeing regulatory affairs, including therapeutics and vaccine development, devices, diagnostics, and clinical trials.
  • “I have been watching Alpha Tau’s development with excitement for quite some time,” said Dr. Hahn.

Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 28, 2023
Pancreatic cancer, Restart, SCC, Medical school, Jewish General Hospital, D&O, Alpha, Symantec Endpoint Protection, Marketing, Clinical trial, Skin, Israel Land Authority, Head, G&A, Toxicity, Neck, Trial of the century, Liver cancer, Manager, Cambridge University Hospitals NHS Foundation Trust, Patient, General Hospital, PMDA, Financial result, Carcinoma, Addenbrooke's Hospital, Itch, McGill University, Financial toxicity, Vulva, Safety, D, Pharmaceutical industry, Nursing, Cryptocurrency, Medicine

JERUSALEM, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported second quarter 2023 financial results and provided a corporate update.

Key Points: 
  • JERUSALEM, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported second quarter 2023 financial results and provided a corporate update.
  • Alpha Tau expects to develop the land toward a future standalone global headquarters and lead manufacturing site, including significantly expanded areas for Alpha DaRT manufacturing, staff, and R&D facilities.
  • Targeting recruitment in the Canadian liver cancer feasibility trial to begin in the second half of 2023.
  • Planned submission of Alpha DaRT pivotal trial results in head and neck SCC to Japan’s regulatory authority, PMDA in the second half of 2023, for potential marketing authorization.

Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT

Retrieved on: 
Thursday, August 17, 2023
Restart, Histology, Alpha, Head, Toxicity, CMO, Neck, Manager, Patient, Itch, Hadassah Medical Center, Toxic epidermal necrolysis, Recurrence, Alpha Sigma Tau, Safety, Pharmaceutical industry, Medical imaging

JERUSALEM, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today initial long-term safety and tumor control outcomes for patients with unresectable, recurrent, or locally advanced head and neck or skin tumors treated Alpha DaRT across four prospective trials conducted at several international institutions.

Key Points: 
  • JERUSALEM, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today initial long-term safety and tumor control outcomes for patients with unresectable, recurrent, or locally advanced head and neck or skin tumors treated Alpha DaRT across four prospective trials conducted at several international institutions.
  • Between February 2017 and December 2022, 81 lesions in 71 patients were treated with Alpha DaRT in four prospective feasibility trials whose objective was to assess early toxicity and tumor response outcomes.
  • There was no grade 2 or higher late toxicities observed in this cohort, defined as toxicities occurring six months or later after Alpha DaRT treatment.
  • “We are excited to share these longer-term data on outcomes from treatment with Alpha DaRT,” noted Uzi Sofer, Alpha Tau’s CEO.

Brooks Launches ReStart Recommerce Program to Support Sustainability Goals and Increase Access to the Run

Retrieved on: 
Thursday, July 6, 2023
Sports, Other Retail, Environment, Specialty, Other Sports, Online Retail, Fashion, Retail, Partnership, MSRP, Life, Ghost, Glycerol, Multimedia, Brooks, Brooks Sports, Hyperion, Restart, Corporation, Recommerce, Trove, News, Corporate responsibility, Industrial design

Brooks Running is proud to launch ReStart , a new recommerce program that will refurbish and resell gently used Brooks footwear in the US.

Key Points: 
  • Brooks Running is proud to launch ReStart , a new recommerce program that will refurbish and resell gently used Brooks footwear in the US.
  • ReStart keeps gently used gear on the run and enters the brand into the growing recommerce market.
  • (Graphic: Business Wire)
    “I'm incredibly excited to share the news of Brooks’ new recommerce program in partnership with Trove,” said Melanie Allen, Chief Marketing Officer at Brooks.
  • ReStart advances those goals by extending the life of gently used Brooks gear and providing a revenue source for future sustainability initiatives.

Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 23, 2023
Pancreatic cancer, Restart, Rat, Medical school, Jewish General Hospital, Alpha, Symantec Endpoint Protection, Marketing, Clinical trial, Skin cancer, Skin, Head, G&A, Toxicity, Lung, Liver cancer, Ministry, Environmental protection, Cambridge University Hospitals NHS Foundation Trust, Patient, JAMA Network Open, General Hospital, PMDA, Carcinoma, Addenbrooke's Hospital, Financial result, McGill University, Biophysical environment, Mouse, Alpha Sigma Tau, Vulva, Health Canada, Pharmaceutical industry, Dietary supplement, Nursing, Cryptocurrency, Medicine

- Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer, which began enrolling patients in March -

Key Points: 
  • - Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer, which began enrolling patients in March -
    - Received Health Canada approval in March to initiate a liver cancer feasibility trial, with recruitment targeted to begin mid-year -
    JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported first quarter 2023 financial results and provided a corporate update.
  • In parallel, we are preparing for potential future product launches by advancing our commercial planning activities and solidifying our supply chain.
  • Alpha Tau remains adequately capitalized to support all of these programs over the coming years," he concluded.
  • Planned submission of Alpha DaRT pivotal trial results in head and neck cancer to Japan’s regulatory authority, PMDA in the second half of 2023, for potential marketing authorization.

Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open

Retrieved on: 
Thursday, May 11, 2023
Restart, CT, Alpha Sigma Tau, Alpha, Symantec Endpoint Protection, Sun Yat-sen University Cancer Center, Safety, Skin cancer, Skin, Quality of life, Toxicity, Radiation therapy, Dart, MD, JAMA Network Open, Patient, Carcinoma, Memorial Sloan Kettering Cancer Center, Clinical research, Toxic epidermal necrolysis, Pharmaceutical industry, Medical imaging

JERUSALEM, May 11, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the publication of the results of its US multicenter pilot trial in JAMA Network Open.

Key Points: 
  • JERUSALEM, May 11, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the publication of the results of its US multicenter pilot trial in JAMA Network Open.
  • The pilot study was designed to evaluate the feasibility of Alpha DaRT in treating ten subjects with malignant skin and superficial soft tissue tumors.
  • Alpha Tau CEO Uzi Sofer commented, “The publication of the pilot trial results in JAMA Network Open is a moment of great pride for all of us at Alpha Tau.
  • Given the promising results of this pilot trial, we look forward to the results of the pivotal ReSTART trial.”